TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11217593

Group type: EXPERIMENTAL
Intervention: Z100 (3M Dental Products)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Prisma TPH (Caulk/Dentsply)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Clearfil Ray‐Posterior (Kuraray Co. Ltd.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: All materials
Number of subjects: 38
Study: 8955997

Group type: EXPERIMENTAL
Intervention: 1,100 ppm fluoride dentifrice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 250 ppm fluoride dentifrice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 30
Study: 7837145

Group type: EXPERIMENTAL
Intervention: Patients with SLE
Number of subjects: 70

Group type: COMPARATOR
Intervention: Patients with RA
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 70
Study: 3131470

Group type: EXPERIMENTAL
Intervention: Intravenous desmopressin acetate (0.4 microgram/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intranasal drops and intranasal spray of desmopressin acetate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Venous occlusion test
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous desmopressin acetate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Euglobulin lysis time, t-PA activity, t-PA antigen levels, and t-PA fast-acting inhibitor (PAI) level
Number of subjects: 9
Study: 30672235

Group type: EXPERIMENTAL
Intervention: Combined treatment of superficial needling technique and mild moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Warm acupuncture
Number of subjects: 60
Study: 28760148

Group type: COMPARATOR
Intervention: Exercise program for older married couples (CG)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Non-couple group (NCG)
Number of subjects: 93
Study: 23778124

Group type: EXPERIMENTAL
Intervention: Stereotactic central lateral thalamotomy (CLT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 8
Study: 21558582

Group type: EXPERIMENTAL
Intervention: 3-month intervention (INT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: usual care (UC)
Number of subjects: 41
Study: 19705041

Group type: EXPERIMENTAL
Intervention: Pre-cleaning with a robot
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ordinary cleaning without the use of a robot
Number of subjects: 12
Study: 16769912

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICDs
Number of subjects: 400

Group type: COMPARATOR
Intervention: Single-chamber ICDs
Number of subjects: 400

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 400
Study: 15042531

Group type: EXPERIMENTAL
Intervention: Rituximab in combination with fludarabine and cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased dosing intensity and frequency of rituximab
Number of subjects: 0
Study: 11377899

Group type: COMPARATOR
Intervention: Latanoprost 0.005% alone (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracameral acetylcholine alone (Group 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% with intracameral acetylcholine (Group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication (controls, Group 4)
Number of subjects: 0
Study: 9442547

Group type: EXPERIMENTAL
Intervention: Sulpiride (200 mg daily for 30 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7955519

Group type: EXPERIMENTAL
Intervention: HIV-1LAI recombinant gp160 (rgp160) vaccine, 50-micrograms doses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HIV-1LAI recombinant gp160 (rgp160) vaccine, Group 1 (0, 1, 2, and 5 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HIV-1LAI recombinant gp160 (rgp160) vaccine, Group 2 (0, 1, 2, 3, and 4 months)
Number of subjects: 30
Study: 3043359

Group type: EXPERIMENTAL
Intervention: ticarpen tobramycin
Number of subjects: 87

Group type: COMPARATOR
Intervention: ticarpen moxalactam
Number of subjects: 87
Study: 31736069

Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg/mL intravenously)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Misoprostol (800 μg rectally)
Number of subjects: 150
Study: 31016527

Group type: EXPERIMENTAL
Intervention: 0.9% normal saline (IS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 5% hypertonic saline (HS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: double-distilled water (SW)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study: 28320406

Group type: EXPERIMENTAL
Intervention: Three-session manualised psychosocial group intervention and BBV transmission information booklet plus treatment as usual (TAU)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Information booklet plus treatment as usual (TAU)
Number of subjects: 99
Study: 25569072

Group type: EXPERIMENTAL
Intervention: Xenogenic (porcine) acellular dermal matrix (XADM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hydrogen peroxide and sodium hypochlorite solution (control)
Number of subjects: 36
Study: 23261792

Group type: COMPARATOR
Intervention: Watching videos
Number of subjects: 30

Group type: COMPARATOR
Intervention: Social contingent reinforcement and vocal modeling with an adult
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Playing alone with small toys
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Playing alone with large toys
Number of subjects: 30
Study: 22022214

Group type: EXPERIMENTAL
Intervention: Aflapin(®) 100 mg daily for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18438112

Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction with pouch
Number of subjects: 138

Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction without pouch
Number of subjects: 138
Study: 21901256

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum with fructo-oligosaccharides (Fos) and lifestyle modification
Number of subjects: 66

Group type: COMPARATOR
Intervention: Lifestyle modification alone
Number of subjects: 66
Study: 15988404

Group type: EXPERIMENTAL
Intervention: Antithyroid drugs (methimazole 5-20 mg/die/os) and diphosphonates (alendronate 10 mg/die/os)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Antithyroid drugs only
Number of subjects: 26
Study: 12629097

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (30 micro g/kg sc twice daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Estrogen (ethinyl estradiol) with rhIGF‐I
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: rhIGF‐I
Number of subjects: 65
Study: 9619927

Group type: EXPERIMENTAL
Intervention: Double latex gloving without a disposable protective glove liner (Group 1)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Double latex gloving with a disposable protective glove liner (Group 2)
Number of subjects: 118
Study: 7698300

Group type: EXPERIMENTAL
Intervention: rhIL-3 (10 micrograms/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rhIL-3
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control cycles (CHOP chemotherapy)
Number of subjects: 32
Study: 2642668

Group type: EXPERIMENTAL
Intervention: Morphine-proglumide mixtures (proglumide doses per demand: 0, 50 micrograms, 100 micrograms, or 50 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Morphine (demand dose 3 mg; infusion rate 0.36 mg/hr; lockout time 2 minutes; hourly maximum dose 15 mg/hr)
Number of subjects: 80
Study: 981326

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31924543

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks, IAI 2 mg every 8 weeks after 5 monthly doses
Number of subjects: 54

Group type: COMPARATOR
Intervention: Laser control
Number of subjects: 54
Study: 29888580

Group type: EXPERIMENTAL
Intervention: Bee-venom acupuncture (5 to 15 bee stings at Ashi-points or acupoints, retained for about 5 min, once every other day for 8 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Methotrexate (10 mg, once a week) and Celecoxib (0.2 g, once a day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (Bee-venom acupuncture and control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bee-venom acupuncture
Number of subjects: 120
Study: 25772957

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 adrenaline (Group A)
Number of subjects: 194

Group type: COMPARATOR
Intervention: 2% lignocaine/HCl with 1:100,000 adrenaline (Group B)
Number of subjects: 194
Study: 23522723

Group type: EXPERIMENTAL
Intervention: Step‐N‐Tune activity monitor
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Activ4Life Pro V3.8 activity monitor
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intelligent Device for Energy Expenditure and Activity
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy control group (n=12)
Number of subjects: 12
Study: 21567259

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 338
Study: 18840204

Group type: EXPERIMENTAL
Intervention: 24% oral sucrose solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 40
Study: 16861101

Group type: EXPERIMENTAL
Intervention: Risperidone (flexible dosing starting at 0.02 mg/kg/day, titrated up to 0.06 mg/kg/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 12974590

Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sodium Nitroprusside
Number of subjects: 30
Study: 10755740

Group type: COMPARATOR
Intervention: Morphine 0 mg/70 kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Morphine 4 mg/70 kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Morphine 8 mg/70 kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Morphine 16 mg/70 kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Morphine 32 mg/70 kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Morphine (lowest and highest doses repeated)
Number of subjects: 5
Study: 8677754

Group type: COMPARATOR
Intervention: High dose LPS (1 microgram/ml)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lower LPS concentration (1 ng/ml)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TNF-alpha and IL-6 mRNA levels
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TNF and IL-6 mRNA half-life
Number of subjects: 35
Study: 1577028

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 6694236

Group type: EXPERIMENTAL
Intervention: Early tracheostomy (34 patients)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Late tracheostomy (40 patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Overall population (74 patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Rigid-posture, head-injured patients
Number of subjects: 74
Study: 29336645

Group type: EXPERIMENTAL
Intervention: Supervised individually tailored exercise program (4-6 weeks), aerobic endurance, muscle strength, and relaxation exercises, administered twice a week
Number of subjects: 46

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 46
Study: 26607843

Group type: EXPERIMENTAL
Intervention: Screen time (each additional hour)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Outdoor playtime
Number of subjects: 497
Study: 26374480

Group type: EXPERIMENTAL
Intervention: 1-year multicomponent intervention including self-help materials, tailored newsletters, and motivational interviewing counseling calls
Number of subjects: 801
Study: 23211420

Group type: EXPERIMENTAL
Intervention: LCPUFA (n-3 long-chain polyunsaturated fatty acids) supplementation at 84 g/day from day 60 of gestation through 21-day lactation and until day 30 of second gestation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control sows (CON) fed standard gestation and lactation diets
Number of subjects: 117
Study: 21769058

Group type: EXPERIMENTAL
Intervention: Nicotine (21 mg transdermal patch)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (transdermal patch)
Number of subjects: 8
Study: 18392378

Group type: EXPERIMENTAL
Intervention: Temporary biatrial pacing
Number of subjects: 98

Group type: COMPARATOR
Intervention: No biatrial pacing (control)
Number of subjects: 98
Study: 17201614

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 16429181

Group type: EXPERIMENTAL
Intervention: Cervical preflaring with LA Axxess burs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cervical preflaring with ProTaper instruments
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cervical preflaring with Gates‐Glidden drills
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cervical preflaring with K3 Orifice Opener instruments
Number of subjects: 50

Group type: COMPARATOR
Intervention: No cervical preflaring (Control)
Number of subjects: 50
Study: 11137838

Group type: EXPERIMENTAL
Intervention: Double Umbrella (DU)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Wire Coil (WC)
Number of subjects: 38
Study: 9042638

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2c plus standard induction chemotherapy (three cycles of cyclophosphamide/vincristine/doxorubicin and cisplatin/etoposide plus subcutaneous IFN-alpha-2c)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 85
Study: 8198267

Group type: EXPERIMENTAL
Intervention: Epidural alfentanil (1 mg along with 0.2 mg/h and 0.2-mg boluses on demand)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Subcutaneous alfentanil (1 mg along with 0.2 mg/h and 0.2-mg boluses on demand)
Number of subjects: 12
Study: 3440099

Group type: EXPERIMENTAL
Intervention: N-desmethylclobazam (NDMC) 30 mg single dose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clobazam 30 mg single dose
Number of subjects: 16
Study: 29873093

Group type: EXPERIMENTAL
Intervention: Indoor play space
Number of subjects: 496

Group type: COMPARATOR
Intervention: Portable play equipment
Number of subjects: 496

Group type: COMPARATOR
Intervention: Outdoor physical environment
Number of subjects: 496
Study: 27554227

Group type: EXPERIMENTAL
Intervention: Dexem group (15 mL of 0.75% ropivacaine plus dexmedetomidine, 1 µg/kg bolus, followed by 0.2 µg/kg/hour infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexem group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ropin group
Number of subjects: 30
Study: 26335989

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23537008

Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Myomectomy (MY)
Number of subjects: 0
Study: 21288094

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 4065
Study: 18496358

Group type: EXPERIMENTAL
Intervention: Management with a PAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative flow measurement device
Number of subjects: 0
Study: 16540957

Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl (co-sedation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 30
Study: 14515937

Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale of Spasticity (MAS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Passive Range of Movement (PROM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Modified Tardieu Scale (MTS)
Number of subjects: 18
Study: 10341684

Group type: EXPERIMENTAL
Intervention: MRI assessment of resected specimens
Number of subjects: 26

Group type: COMPARATOR
Intervention: Histopathological examination
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MR imaging of resected specimens
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MR examinations
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MRI assessment
Number of subjects: 26
Study: 7498356

Group type: EXPERIMENTAL
Intervention: Informed consent
Number of subjects: 3217

Group type: EXPERIMENTAL
Intervention: Randomised consent (for experimental therapy)
Number of subjects: 3217

Group type: EXPERIMENTAL
Intervention: Randomised consent (for standard therapy)
Number of subjects: 3217
Study: 2031498

Group type: EXPERIMENTAL
Intervention: Active treatment in TOHP (Trials of Hypertension Prevention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active treatment in HPT (Hypertension Prevention Trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (black control subjects)
Number of subjects: 0
Study: 7214987

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam intravenous supplement
Number of subjects: 113

Group type: COMPARATOR
Intervention: Intravenous placebo (solvent of diazepam only)
Number of subjects: 113
Study: 29232526

Group type: EXPERIMENTAL
Intervention: Parental support program based on motivational interviewing (MI) delivered by nurses in Swedish child health services, with nine sessions over ∼39 months.
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Control group received usual healthcare.
Number of subjects: 1355
Study: 25794890

Group type: EXPERIMENTAL
Intervention: Delayed surgical oophorectomy during the midluteal phase of the menstrual cycle
Number of subjects: 740

Group type: COMPARATOR
Intervention: Immediate surgical oophorectomy
Number of subjects: 740
Study: 23018784

Group type: EXPERIMENTAL
Intervention: Zoledronate (ZOL)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 107
Study: 21109054

Group type: EXPERIMENTAL
Intervention: Cervical spine joint mobilization
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sedative massage
Number of subjects: 23
Study: 18992135

Group type: EXPERIMENTAL
Intervention: COACH prompting system
Number of subjects: 6
Study: 16816950

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12686397

Group type: EXPERIMENTAL
Intervention: Working memory tasks of mental calculation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trail Making Test (TMT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Kana Pick-out Test
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 24
Study: 10666970

Group type: EXPERIMENTAL
Intervention: Galloy restorations sealed with PAAMA 2 dentine adhesive system
Number of subjects: 37

Group type: COMPARATOR
Intervention: Tytin restorations without adhesive sealer
Number of subjects: 37
Study: 8689371

Group type: EXPERIMENTAL
Intervention: Intensive outreach case management for periods ranging from 15 to 52 months after discharge
Number of subjects: 292

Group type: COMPARATOR
Intervention: Standard aftercare services
Number of subjects: 292
Study: 1715503

Group type: EXPERIMENTAL
Intervention: Digital rectal screening and prostate-specific antigen (PSA) measurement
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Transrectal ultrasonography
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 814
Study: 6630564

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 80
Study: 2858618

Group type: EXPERIMENTAL
Intervention: Liquid crystal colour thermography
Number of subjects: 80
Study: 29678995

Group type: EXPERIMENTAL
Intervention: Intermittent oxygen saturation monitoring
Number of subjects: 210

Group type: COMPARATOR
Intervention: Continuous oxygen saturation monitoring
Number of subjects: 210
Study: 27077994

Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG) - observed pictures showing landscapes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EEG-based brain mapping during AOT
Number of subjects: 20

Group type: COMPARATOR
Intervention: EEG-based brain mapping
Number of subjects: 20
Study: 24687880

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (OnabotA) 150 U
Number of subjects: 0

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA (OnabotA) 75 U
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (OnabotA) 155-195 U
Number of subjects: 0
Study: 22427481

Group type: EXPERIMENTAL
Intervention: IDX320 50 mg once daily for 3 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IDX320 100 mg once daily for 3 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IDX320 200 mg once daily for 3 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IDX320 400 mg once daily for 3 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IDX320 200 mg twice daily for 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19968614

Group type: EXPERIMENTAL
Intervention: Antireflux stent (Esophageal Z-Stent with Dua antireflux valve; n = 28)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional stent (Esophageal Z-stent, Ultraflex or Wallstent; n = 37)
Number of subjects: 65
Study: 18356253

Group type: EXPERIMENTAL
Intervention: Bilateral fetal striatal allografts
Number of subjects: 2
Study: 15719258

Group type: EXPERIMENTAL
Intervention: beta1Gly49 polymorphism
Number of subjects: 80

Group type: COMPARATOR
Intervention: other studied polymorphisms
Number of subjects: 80
Study: 14656275

Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel (TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer drugs added to carboplatin-paclitaxel (TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-idiotype CA 125 antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor (EGFR) modulation
Number of subjects: 0
Study: 10606017

Group type: EXPERIMENTAL
Intervention: Commercial ELISA for detecting serum antibody to Neospora caninum
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Immunofluorescent antibody test (IFAT)
Number of subjects: 1171
Study: 8750128

Group type: EXPERIMENTAL
Intervention: Siemens Servo 300 ventilator
Number of subjects: 7

Group type: COMPARATOR
Intervention: Siemens Servo 900 C ventilator
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Trigger sensitivities of -1 cmH2O, -2 cmH2O, and flow triggering with Siemens Servo 300 ventilator
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Different levels of CPAP with Siemens Servo 300 ventilator
Number of subjects: 7